Skip to main content
. 2019 Sep 25;9:13902. doi: 10.1038/s41598-019-50157-5

Figure 4.

Figure 4

Etoposide-mediated apoptosis is mitigated in GRK2 overexpressing cells. (A–D) Tva-expressing UW228 (A,B) and Daoy cells (C,D) were infected with pRDAV-mycGRK2-IRES-eGFP virus to express human GRK2 or the control virus pRDAV-eGFP, grown for 8 days and then treated with etoposide (10 µg/ml for UW228, 8 µg/ml for Daoy) for the indicated times. Flow cytometry was used to assess apoptosis (AnnexinV/7AAD) in the eGFP-expressing cells. (B,D) are means ± SEM of early + late apoptosis of three biological replicates for each of these two cell lines; p-values: in B * represents p = 0.04 and ** represents p = 0.007; in D * represents p = 0.03 and ** represents p = 0.001, using unpaired student’s t-test. (E,F) Western blot for PARP1 cleavage in lysates of UW228 (E) or Daoy cells (F) infected with GRK2 or control vectors as in (AD) that were treated with etoposide (10 µg/ml for UW228; 8 µg/ml for Daoy) for the indicated times. Supplemental Figure S4 provides a GRK2 western blot of cells used in (E,F) with longer exposure, to show native GRK2 level compared to overexpressed.